The fourth cohort of an ongoing phase 1/2 has dosed its first patient with TTX-MC138 in advanced solid tumors.

Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET. Company Participants. Douglas Onsi - President ...

Petrobras discovered hydrocarbons in an exploratory well in North Brava block in the Campos basin presalt, 105 km off the ...

AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that its ...

TransCode begins patient dosing in Cohort 4 of phase 1 trial with TTX-MC138 to treat metastatic cancer: Boston Monday, March 31, 2025, 18:00 Hrs [IST] TransCode Therapeutics, Inc.

Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...

For prolonged antithrombotic treatment after percutaneous coronary intervention (PCI), clopidogrel monotherapy was more ...

Researchers have found in a new study that oral anticoagulants OAC-naive patients experienced a smaller increase in stroke or ...

ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition. DOYLESTOWN, Pa ...

LEXINGTON, MA, USA I March 31, 2025 I Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...